Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study

Treatment Effect of AC5-Significantly Shortening of Time To Hemostasis vs Control- Was Consistent Whether Patients Were Taking Antiplatelet Therapy or Not FRAMINGHAM, MA ARTH,(Marketwired Oct 31, 2016) Arch Therapeutics, Inc. (OTCQB: ARTH) ( Arch or the Company ), developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, reports additional positive data in its recently completed single-center, randomized, single-blind prospective clinical study (NCT 02704104) of the AC5 Topical Hemostatic
http://bit.ly/2e5ZBqL

GreenVision Systems and Hemp Adobe Form Strategic Alliance to Manufacture Hemp Products in Puerto Rico

LAS VEGAS, NV SVSN, (Marketwired Oct 31, 2016) StereoVision Entertainment Inc. (OTC PINK: SVSN), a publicly traded Nevada company, announced today that their jointly owned Puerto Rico medical cannabis and hemp products manufacturing company GreenVision Systems has formed a strategic alliance with Hemp Adobe to manufacture for export and for Puerto Rico s domestic markets an assortment of hemp based home building products. Hemp Adobe (http://hempadobe.com) is a pioneer in the development of hemp-based products for the construction industry, said
http://bit.ly/2e5KTQC

Nimbo Tracking, an IGEN Networks Corporation Company, to showcase Pre-Load Dealership Platform at The SEMA Show November 1-4

MURRIETA, Calif., Oct. 31, 2016, IGEN, (GLOBE NEWSWIRE) Nimbo Tracking, a wholly owned subsidiary of IGEN Networks Corp (the “Company” or “IGEN”) (OTCQB:IGEN) (CSE:IGN), announces it will exhibit at The SEMA Show next week from November 1 to November 4, 2016 at the Las Vegas Convention Center. The SEMA Show is the premier automotive specialty products trade event in the world that attracts more than 100,000 industry leaders from more than 100 countries. Attendees are invited to visit Booth
http://bit.ly/2e5KgXj

Skyline Medical and GLG Pharma Enter into Partnership to Develop Diagnostic Tests for Skyline’s STREAMWAY System

Skyline to be exclusive reseller MINNEAPOLIS, Sept. 21, 2016, SKLN, (GLOBE NEWSWIRE) Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces the signing of a partnership and exclusive reseller agreement with GLG Pharma, LLC (“GLG”). Under the terms of the agreement, GLG intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. Skyline Medical will issue common stock to
http://bit.ly/2e5LUrZ

TAG Oil Announces Definitive Agreement to Acquire Assets Located in Australia’s Surat Basin

VANCOUVER, Oct. 31, 2016, TAOIF, TAO, /PRNewswire/ Oil and gas exploration and production company, TAG Oil Ltd. (TSX: TAO and OTCQX: TAOIF, TAG ), is pleased to announce that its wholly owned Australian subsidiary, Cypress Petroleum Pty Ltd. ( Cypress ), has entered into a definitive asset purchase agreement (the Definitive Agreement ) with Southern Cross Petroleum & Exploration Pty Ltd. ( Southern Cross ), to acquire a 100% interest, subject to underlying royalties, in Petroleum Lease 17 ( PL 17 ) and all related assets, which
http://bit.ly/2e5Ix4s

Skyline Medical Appoints J. Melville Engle and Timothy A. Krochuk to its Board of Directors

MINNEAPOLIS, Oct. 27, 2016, SKLN, (GLOBE NEWSWIRE) Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces the appointments of Timothy A. Krochuk and J. Melville (“Mel”) Engle to its Board of Directors, effective as of today. These appointments increase the number of Directors to five, all of whom are independent directors. “We are delighted to welcome such talented and experienced professionals as Tim and Mel to the
http://bit.ly/2fkVITS

Airborne Wireless Network Closes Second $250,000 Private Placement Transaction

SIMI VALLEY, Calif., Oct. 27, 2016, ABWN, /PRNewswire/ AIRBORNE WIRELESS NETWORK (OTC QB: ABWN) is pleased to announce that on October 25, 2016, it closed a second $250,000 private placement funding transaction. Pursuant to that transaction, the Company sold 312,500 shares of its common stock for a purchase price of $0.80 per share, for a total of $250,000. In addition, pursuant to that transaction, the Company granted to the purchaser of those securities a warrant to purchase for a
http://bit.ly/2fjBTwn

Green Cures & Botanical Distribution Inc. (OTC PINK: GRCU) Announces Network Marketing Campagn For Roberto Duran Champion Energy Shots

INGLEWOOD, CA GRCU, (Marketwired Oct 27, 2016) Green Cures & Botanical Distribution, Inc. (OTC PINK: GRCU) has announced a new Network Marketing Campaign for its recently completed Roberto Duran Champion ® Energy Shots. Produced under an exclusive license, these products are available in two delicious flavors of Berry and Orange. The beautifully designed energy shots live up to the legendary status of famed Panamanian boxer Roberto Duran widely regarded as one of the greatest boxers of all time.
http://bit.ly/2fjFn1S

PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline

Hancock, MD, Oct. 27, 2016, PTLF, (GLOBE NEWSWIRE) Hancock, MD Innovative veterinary health company, PetLife Pharmaceuticals, Inc. (OTC QB: PTLF), announced today a partnership with Lumleian, LLC, a life sciences advisory firm based in Boston, MA. Working together, PetLife and Lumleian will seek to advance PetLife s clinical and commercial pipeline in the United States, including securing capital to develop its lead product, Vitalzul™, for the treatment of various veterinary oncology indications. Dr. Salvagno, CEO of PetLife Pharmaceuticals, noted,
http://bit.ly/2fjD9iW

Medical Marijuana, Inc. Investment AXIM(R) Biotechnologies, Inc. Secures Funding to Continue Pharma Clinical Trials Program in Cannabinoid R&D

Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple Indications SAN DIEGO, CA AXIM, MJNA, (Marketwired October 26, 2016) Medical Marijuana, Inc. (OTC PINK: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications. AXIM® Biotech s most
http://bit.ly/2ffIhoy